144-Hour Visa-Free Transit Unlocks Wonders of Yunnan: "Yunnan: A Many-Splendored Life" Awaits You
21.10.2024 03:00:00 CEST | Business Wire | Press release
With the expansion of China's 144-hour visa-free transit policy, Yunnan Province has opened its doors wider to international travelers, extending to include Kunming, Lijiang, Yuxi, Pu'er, Chuxiong, Dali, Xishuangbanna, Honghe, Wenshan, and nine other cities and prefectures. Travelers from 54 countries can enter Yunnan through Kunming Changshui International Airport, Lijiang Sanyi International Airport, and Mohan Railway Port by presenting valid international travel documents and onward tickets within 144 hours. This allows for a spontaneous Yunnan tour without cumbersome visa processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241020373774/en/
Countries Eligible for the 144-Hour Visa-Free Transit Policy in Yunnan Province (Graphic: Business Wire)
"Yunnan: A Many-Splendored Life" is a lifestyle with fantastic nature and great ecosystems. Yunnan boasts three World Natural Heritage Sites – Three Parallel Rivers, Chengjiang Fossil Site, and Yunnan Stone Forest. Snow-capped plateaus stand alongside peaks and canyons, complemented by rivers, lakes, and forests, to create a magnificent scenery. Yunnan is known as a blooming "Spring City": camellias grace Dali, flamboyant flowers brighten Xishuangbanna, Ottelia acuminata sways on Lugu Lake, and winter cherry blossoms adorn Wuliang Mountain. Kunming Dounan Flower Market allows travelers to take a piece of Yunnan's spring home. Yunnan is also home to rare animal species like Yunnan snub-nosed monkeys, Asian elephants, and black-headed gulls.
"Yunnan: A Many-Splendored Life" is a lifestyle with profound culture. Yunnan boasts three World Cultural Heritage Sites – Lijiang Old Town, Honghe Hani Rice Terraces, and Jingmai Mountain Ancient Tea Forests in Pu'er, and eight National Famous Historical and Cultural Cities. Historical corridors like Southern Silk Road and Tea Horse Road reflect Yunnan's foreign trade and cultural exchanges. The Bai's Three-Course Tea, the Naxi's Dongba culture and pictographs, the Yi's Torch Festival, and the Dai's Water-Splashing Festival and Peacock Dance highlight its vast cultural legacy.
"Yunnan: A Many-Splendored Life" is a green and healthy lifestyle. Yunnan is an ideal destination for wellness tourism, outdoor activities, and international sports events, with lush mountains, clear waters, and spring-like climate year-round. Eco-friendly products, including Yunnan's flowers, tea, fruits, vegetables, medicinal herbs, and coffee, along with dishes like Mushroom feasts, Yunnan ham, cross-bridge rice noodles, flower cakes, and steam pot chicken, create unforgettable memories.
Yunnan offers boundless natural beauty, a warm living atmosphere, and a healthy lifestyle. As the 144-hour visa-free travelers swarm in, Yunnan will extend greater hospitality and invite them to experience its unique charm and beauty.
Video link:
https://youtu.be/IIdperTx2EA?si=KsT_M88yNRHwJe26
View source version on businesswire.com: https://www.businesswire.com/news/home/20241020373774/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press release
SkyDefender is a multi-layer, multi-domain Integrated Air and Missile Defence system providing full protection against all types of air threats, on land, at sea and in space. SkyDefender integrates a network of advanced sensors and effectors with a versatile command and control (C2) system. With its open and modular architecture, it is fully compatible with existing air defence systems. Combining Thales’ expertise in cybersecurity and advanced artificial intelligence through cortAIx, Thales AI accelerator, SkyDefender enables operational superiority and proactive defence against cyberattacks and evolving threats. Thales is capable of delivering this critical protection globally from today. As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press release
Japan is one of the world's most important pharmaceutical markets after the US and Europe. Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well as speciality care medicines in Japan, including a blockbuster drug. The agreement with Neupharma includes upfront and milestone payments of up to CHF 83.5 million as well as royalties of up to 20% on sales. The population of available patients eligible for corticorelin treatment associated with peritumoral brain edema is estimated at 60,000 in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually. Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rig
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 202510.3.2026 22:52:00 CET | Press release
- Sustainable Growth Driven by International Expansion - Significant Increase Across Key Metrics Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310410214/en/ Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025 (Photo: AETOSWire) Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264. The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom